MetLife Investment Management LLC Lowers Stock Holdings in Insulet Co. (NASDAQ:PODD)

MetLife Investment Management LLC reduced its stake in Insulet Co. (NASDAQ:PODD) by 2.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,405 shares of the medical instruments supplier’s stock after selling 509 shares during the period. MetLife Investment Management LLC’s holdings in Insulet were worth $4,982,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. Blue Trust Inc. raised its holdings in shares of Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 58 shares in the last quarter. International Assets Investment Management LLC purchased a new stake in shares of Insulet in the 2nd quarter worth approximately $32,000. Venturi Wealth Management LLC boosted its stake in shares of Insulet by 633.3% during the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 133 shares in the last quarter. UMB Bank n.a. increased its holdings in Insulet by 81.0% during the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after buying an additional 81 shares during the period. Finally, CVA Family Office LLC raised its stake in Insulet by 138.1% in the second quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock worth $50,000 after buying an additional 145 shares in the last quarter.

Insulet Stock Performance

Shares of PODD stock opened at $266.78 on Monday. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $279.40. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The stock has a market cap of $18.71 billion, a PE ratio of 45.68, a price-to-earnings-growth ratio of 4.08 and a beta of 1.22. The business has a 50-day simple moving average of $244.40 and a 200-day simple moving average of $214.14.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on PODD. Morgan Stanley lifted their price target on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a report on Monday, November 11th. Canaccord Genuity Group lifted their target price on Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Piper Sandler increased their price target on shares of Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Barclays lifted their price objective on shares of Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research report on Monday, November 11th. Finally, UBS Group increased their target price on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research report on Friday, August 9th. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $253.27.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.